ZFIN ID: ZDB-FISH-150901-12164
Fish name: vhlhu2117/hu2117
Genotype: vhlhu2117/hu2117
Targeting Reagent: none
HUMAN DISEASE MODELED by vhlhu2117/hu2117
Human Disease Conditions Citations
von Hippel-Lindau disease standard conditions Martins Metelo et al., 2015
clear cell renal cell carcinoma standard conditions Noonan et al., 2016
familial erythrocytosis 2 standard conditions van Rooijen et al., 2009
GENE EXPRESSION
Gene expression in vhlhu2117/hu2117
RNA expression
Expressed Gene Structure Conditions Figures
alas2 standard conditions Table 1 from Kim et al., 2020
baxa control Fig. 1 from Essers et al., 2015
gamma ray Fig. 1 from Essers et al., 2015
bbc3 control Fig. 1 from Essers et al., 2015
gamma ray Fig. 1 from Essers et al., 2015
birc2 control Fig. 4 from Essers et al., 2015
gamma ray Fig. 4 from Essers et al., 2015
birc5a control Fig. 4 from Essers et al., 2015
gamma ray Fig. 4 from Essers et al., 2015
cdkn1a control Fig. 1 from Essers et al., 2015
gamma ray Fig. 1 from Essers et al., 2015
cflara control Fig. 4 from Essers et al., 2015
gamma ray Fig. 4 from Essers et al., 2015
cxcr4a standard conditions Fig. 2 from van Rooijen et al., 2018
egln3 standard conditions Table 1 from Kim et al., 2020
gata1a standard conditions Table 1 from Kim et al., 2020
ldha standard conditions Fig. 5 with image from Marchi et al., 2020
Fig. S9 with image from van der Velden et al., 2011
chemical treatment by environment: betamethasone dipropionate Fig. 5 with image from Marchi et al., 2020
mknk2b standard conditions Table 1 from Kim et al., 2020
ndufa4b standard conditions Fig. S9 with image from van der Velden et al., 2011
vegfaa standard conditions Table 1 from Kim et al., 2020
PHENOTYPE
Phenotype in vhlhu2117/hu2117
Phenotype Conditions Figures
angiogenesis increased process quality, abnormal standard conditions Fig. 4Fig. 5 from Martins Metelo et al., 2015
capillary loop nephron dilated, abnormal standard conditions Fig. 2 from van Rooijen et al., 2018
capillary loop nephron cxcr4a expression increased amount, abnormal standard conditions Fig. 2 from van Rooijen et al., 2018
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest decreased process quality, abnormal gamma ray Fig. 4 from Essers et al., 2015
erythrocyte differentiation increased process quality, abnormal standard conditions Fig. 4Fig. 5 from Martins Metelo et al., 2015
head ldha expression increased amount, abnormal standard conditions Fig. 5 with image from Marchi et al., 2020
head ldha expression increased amount, abnormal chemical treatment by environment: betamethasone dipropionate Fig. 5 with image from Marchi et al., 2020
heart contraction process quality, abnormal control Fig. 6 from Martins Metelo et al., 2015
intestinal epithelium shape, normal standard conditions Fig. 6 with image from van der Velden et al., 2011
liver color, normal standard conditions Fig. 6 with image from van der Velden et al., 2011
liver ldha expression increased amount, abnormal standard conditions Fig. 5 with image from Marchi et al., 2020
liver ldha expression increased amount, abnormal chemical treatment by environment: betamethasone dipropionate Fig. 5 with image from Marchi et al., 2020
pronephric capsular space increased width, abnormal standard conditions Fig. 2 from van Rooijen et al., 2018
pronephric glomerulus increased size, abnormal standard conditions Fig. 2 from van Rooijen et al., 2018
pronephric podocyte cxcr4a expression increased amount, abnormal standard conditions Fig. 2 from van Rooijen et al., 2018
pronephric proximal convoluted tubule apical-basal polarity, abnormal standard conditions Fig. 1 with image from Noonan et al., 2016
pronephric proximal convoluted tubule diameter, ameliorated chemical treatment by environment: EC 1.14.11.29 (hypoxia-inducible factor-proline dioxygenase) inhibitor Fig. 7 with image from Noonan et al., 2016
pronephric proximal convoluted tubule increased diameter, abnormal standard conditions Fig. 1 with imageFig. 2 with imageFig. 7 with image from Noonan et al., 2016
pronephric proximal convoluted tubule cell botryoidal, abnormal standard conditions Fig. 1 from van Rooijen et al., 2018
pronephric proximal convoluted tubule ciliated epithelial cell disorganized, abnormal standard conditions Fig. 2 with imageFig. 7 with image from Noonan et al., 2016
pronephric proximal convoluted tubule ciliated epithelial cell organization quality, ameliorated chemical treatment by environment: EC 1.14.11.29 (hypoxia-inducible factor-proline dioxygenase) inhibitor Fig. 7 with image from Noonan et al., 2016
pronephric proximal convoluted tubule cytoplasm has extra parts of type pronephric proximal convoluted tubule vesicle, abnormal standard conditions Fig. 3 from van Rooijen et al., 2018
pronephric proximal convoluted tubule cytoplasmic vesicle amount, ameliorated chemical treatment by environment: EC 1.14.11.29 (hypoxia-inducible factor-proline dioxygenase) inhibitor Fig. 7 with image from Noonan et al., 2016
pronephric proximal convoluted tubule cytoplasmic vesicle increased amount, abnormal standard conditions Fig. 1 with imageFig. 7 with image from Noonan et al., 2016
pronephric proximal convoluted tubule epithelial cell decreased amount, abnormal standard conditions Fig. 1 with imageFig. 7 with image from Noonan et al., 2016
pronephric proximal convoluted tubule vesicle increased variability of size, abnormal standard conditions Fig. 3 from van Rooijen et al., 2018
pronephric proximal straight tubule apical-basal polarity, abnormal standard conditions Fig. 1 with image from Noonan et al., 2016
pronephric proximal straight tubule diameter, ameliorated chemical treatment by environment: EC 1.14.11.29 (hypoxia-inducible factor-proline dioxygenase) inhibitor Fig. 7 with image from Noonan et al., 2016
pronephric proximal straight tubule increased diameter, abnormal standard conditions Fig. 1 with imageFig. 2 with imageFig. 7 with image from Noonan et al., 2016
pronephric proximal straight tubule cell botryoidal, abnormal standard conditions Fig. 1 from van Rooijen et al., 2018
pronephric proximal straight tubule ciliated epithelial cell disorganized, abnormal standard conditions Fig. 2 with imageFig. 7 with image from Noonan et al., 2016
pronephric proximal straight tubule ciliated epithelial cell organization quality, ameliorated chemical treatment by environment: EC 1.14.11.29 (hypoxia-inducible factor-proline dioxygenase) inhibitor Fig. 7 with image from Noonan et al., 2016
pronephric proximal straight tubule cytoplasm has normal numbers of parts of type pronephric proximal straight tubule vesicle, normal standard conditions Fig. 3 from van Rooijen et al., 2018
pronephric proximal straight tubule cytoplasmic vesicle amount, ameliorated chemical treatment by environment: EC 1.14.11.29 (hypoxia-inducible factor-proline dioxygenase) inhibitor Fig. 7 with image from Noonan et al., 2016
pronephric proximal straight tubule cytoplasmic vesicle increased amount, abnormal standard conditions Fig. 1 with imageFig. 7 with image from Noonan et al., 2016
pronephric proximal straight tubule epithelial cell decreased amount, abnormal standard conditions Fig. 1 with imageFig. 7 with image from Noonan et al., 2016
pronephros development decreased process quality, abnormal standard conditions Fig. 1Fig. 2Fig. 3 from van Rooijen et al., 2018
proximal convoluted tubule cell population proliferation occurrence, normal standard conditions Fig. 2 from van Rooijen et al., 2018
proximal straight tubule cell population proliferation occurrence, normal standard conditions Fig. 2 from van Rooijen et al., 2018
regulation of cell cycle decreased process quality, abnormal gamma ray Fig. 4 from Essers et al., 2015
whole organism Ab2-mdm2 labeling decreased amount, abnormal gamma ray Fig. 3 from Essers et al., 2015
whole organism Ab2-mdm2 labeling decreased amount, abnormal control Fig. 3 from Essers et al., 2015
whole organism decreased life span, abnormal control Fig. 6 from Martins Metelo et al., 2015
whole organism decreased life span, ameliorated chemical treatment: antimycin A Fig. 4 from Jain et al., 2016
whole organism mknk2b expression increased amount, abnormal standard conditions Table 1 from Kim et al., 2020
whole organism alas2 expression increased amount, abnormal standard conditions Table 1 from Kim et al., 2020
whole organism Ab14-tp53 labeling increased amount, abnormal control Fig. 1 from Essers et al., 2015
whole organism gata1a expression increased amount, abnormal standard conditions Table 1 from Kim et al., 2020
whole organism bbc3 expression increased amount, abnormal gamma ray Fig. 1 from Essers et al., 2015
whole organism baxa expression increased amount, abnormal gamma ray Fig. 1 from Essers et al., 2015
whole organism Ab14-tp53 labeling increased amount, abnormal gamma ray Fig. 1 from Essers et al., 2015
whole organism egln3 expression increased amount, abnormal standard conditions Table 1 from Kim et al., 2020
whole organism cdkn1a expression increased amount, abnormal gamma ray Fig. 1 from Essers et al., 2015
whole organism vegfaa expression increased amount, abnormal standard conditions Table 1 from Kim et al., 2020
whole organism birc5a expression increased amount, abnormal control Fig. 4 from Essers et al., 2015

CITATIONS  (15)